Show simple item record

dc.contributor.authorHowe, M C
dc.contributor.authorChapman, A
dc.contributor.authorKerr, K
dc.contributor.authorDougal, Mark
dc.contributor.authorAnderson, Heather
dc.contributor.authorHasleton, Philip S
dc.date.accessioned2009-08-06T14:40:58Z
dc.date.available2009-08-06T14:40:58Z
dc.date.issued2005-02
dc.identifier.citationNeuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy. 2005, 46 (2):195-201 Histopathologyen
dc.identifier.issn0309-0167
dc.identifier.pmid15693892
dc.identifier.doi10.1111/j.1365-2559.2005.02047.x
dc.identifier.urihttp://hdl.handle.net/10541/76525
dc.description.abstractAIMS: Histopathologists report the presence of neuroendocrine (NE) differentiation in non-small cell lung carcinoma (NSCLC) in up to a third of cases and are often questioned about its clinical relevance. The conclusions of previous studies have been inconsistent. This paper aims to provide an answer by examining a large series together with a comprehensive critique of the literature. METHODS AND RESULTS: Four hundred and thirty-nine cases of NSCLC were examined, immunohistochemically, using antibodies to chromogranin A (CGA), synaptophysin (SYN) and CD56/neural cell adhesion molecule (NCAM). Three hundred and forty-one cases had been treated with surgical resection and the remainder with chemotherapy. The results were compared with clinical outcome. Thity-six percent of cases had positive staining for at least one NE marker. CGA was positive in 5.5% of cases, SYN in 16.5% and NCAM in 28%. There was no association between the presence of NE markers and survival in either the surgically treated group or the chemotherapy-treated group. There was also no association between NE markers and response to chemotherapy in the latter group. CONCLUSIONS: The presence of immunohistochemically detected NE differentiation in NSCLC is not of prognostic significance.
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshAdenocarcinoma
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshCarcinoma, Large Cell
dc.subject.meshCarcinoma, Neuroendocrine
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.meshCarcinoma, Squamous Cell
dc.subject.meshCell Differentiation
dc.subject.meshChromogranin A
dc.subject.meshChromogranins
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshImmunohistochemistry
dc.subject.meshLung Neoplasms
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNeural Cell Adhesion Molecules
dc.subject.meshPrognosis
dc.subject.meshSurvival Analysis
dc.subject.meshSynaptophysin
dc.titleNeuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy.en
dc.typeArticleen
dc.contributor.departmentDepartment of Histopathology, South Manchester University Hospital, Manchester, UK. miles.howe@smuht.nwest.nhs.uken
dc.identifier.journalHistopathologyen
html.description.abstractAIMS: Histopathologists report the presence of neuroendocrine (NE) differentiation in non-small cell lung carcinoma (NSCLC) in up to a third of cases and are often questioned about its clinical relevance. The conclusions of previous studies have been inconsistent. This paper aims to provide an answer by examining a large series together with a comprehensive critique of the literature. METHODS AND RESULTS: Four hundred and thirty-nine cases of NSCLC were examined, immunohistochemically, using antibodies to chromogranin A (CGA), synaptophysin (SYN) and CD56/neural cell adhesion molecule (NCAM). Three hundred and forty-one cases had been treated with surgical resection and the remainder with chemotherapy. The results were compared with clinical outcome. Thity-six percent of cases had positive staining for at least one NE marker. CGA was positive in 5.5% of cases, SYN in 16.5% and NCAM in 28%. There was no association between the presence of NE markers and survival in either the surgically treated group or the chemotherapy-treated group. There was also no association between NE markers and response to chemotherapy in the latter group. CONCLUSIONS: The presence of immunohistochemically detected NE differentiation in NSCLC is not of prognostic significance.


This item appears in the following Collection(s)

Show simple item record